In research published in Nature Medicine today, AI biotech company Owkin has demonstrated for the first time that federated learning (FL) can be used to train deep learning models on data from multiple hospitals on histopathology data without the data leaving hospital firewalls.
The discovery paves the way for AI-powered medical research using larger multi-centric datasets, allowing models to escape the biases of single-centric studies. This has the potential to unlock breakthroughs in precision medicine through the use of secure and privacy-preserving AI.
Using data kept within four leading French hospitals, Owkin built AI models that can accurately predict the future response of triple-negative breast cancer (TNBC) patients to neoadjuvant chemotherapy. By using interpretable AI to extract information from digital pathology slides, Owkin was able to find potential novel biomarkers. This could in the future help funnel patients towards either less toxic treatments or new experimental treatments, improving the personalization of medical care.
The project used federated learning – a collaborative AI framework that preserves data privacy and security through Substra, Owkin’s recently-open sourced software that make every operation traceable using hyperledger technology. The research is the first time that machine learning models have been trained using histopathology data from multiple hospitals without the data leaving the hospitals. Previously, most studies were restricted to simulating FL by artificially splitting data. It is a landmark proofpoint of FL in medical research and represents a breakthrough in the realization of AI’s practical benefit to research.
The study used digital pathology data and clinical information from 650 patients from Institut Curie in Paris, Centre Léon Bérard in Lyon, Gustave Roussy in Villejuif and IUCT Oncopole in Toulouse, making it one of the largest TNBC cohorts of its kind ever assembled for such kind of analysis.
The research builds on Owkin’s pioneering use of FL to enable pharmaceutical companies to collaborate on drug discovery research while safeguarding privacy, security and competitive considerations. The MELLODDY project’s results, published this year, showed that collaborating in AI for drug discovery is possible at industrial scale thanks to FL, a first for the industry. In addition to addressing privacy and security concerns, FL can also simplify data governance issues, removing the need to transfer data and fostering more collaborative research.
Jean du Terrail, lead author and Senior Machine Learning Scientist at Owkin, said:
Thanks to our partners, we are proud to have performed an original federated analysis on medical data in real-life conditions, and the first of its kind on histopathology data. By connecting institutions in a federated manner we were able to reach the critical mass of triple negative breast cancer data necessary for the AI to discover, on its own, histological patterns predictive of the response to treatment. We hope that this proof of concept will inspire medical institutions to collaborate in federated learning networks in order to move research forward while keeping patient data private.
Julien Guérin, Chief Data Officer at Institut Curie in Paris, France, said:
We reached an important milestone with the deployment of this federated learning infrastructure, showing a new cutting-edge approach of building AI in cancer research. We are really happy to have been part of this adventure and hope this will open promising perspectives for the future of patient care.
Dr Guillaume Bataillon, pathologist at IUCT Oncopole in Toulouse, France, and former pathologist at Institut Curie in Paris, France, said:
Through this multidisciplinary partnership, we verify the feasibility of an inter hospital collaborative federated learning approach on a relevant biological question. This allowed us to create pooled heterogeneous dataset in a secure and faster way in order to develop reproductible, transferable and even interpretable models. This proof of concept has the potential to become a tool for therapeutic decision.
Dr Pierre Etienne Heudel, Medical oncologist at Centre Léon Bérard in Lyon, France, said:
The rise of digital pathology coupled with the explosion of different machine learning techniques should enable increasingly precise and personalized medicine. Moreover, the federated learning, achieved in this project by avoiding external data streams, facilitates and secures the process for future daily clinical practice.
Dr Magali Lacroix-Triki, pathologist at Gustave Roussy in Villejuif, France, said:
Digital pathology and AI represent the third revolution in the world of pathology, and pathologists are excited to lead this new change in their practice. Federated learning, pioneering AI research in digital pathology, brings us one step closer to identifying new biomarkers in oncology while ensuring data privacy and security.
Dr Camille Franchet, pathologist at IUCT Oncopole in Toulouse, France, said:
By enabling AI models to be trained on multicentric data without centralization, federated learning unlocks one of the major obstacles in machine learning on medical data with no compromise regarding the respect of personal data.
Owkin is an AI biotechnology company that uses artificial intelligence to find the right treatment for every patient. We bridge shared innovation challenges between biopharma and academic researchers and close the translational gap between complex biology and new drugs.
We use AI to identify new treatments, de-risk and accelerate clinical trials and build diagnostic tools that improve patient outcomes. Using federated learning, a pioneering collaborative AI framework, Owkin enables medical and biopharma partners to unlock valuable insights from siloed datasets while protecting patient privacy and securing proprietary data.
Owkin was co-founded by Thomas Clozel MD, a former assistant professor in clinical onco-haematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016. Owkin has raised over $300 million and became a unicorn through investments from leading biopharma (Sanofi and BMS) and venture funds (Fidelity, GV and BPI, among others).
Method of Research
Subject of Research
Federated learning for predicting histological response to neoadjuvant chemotherapy in triple-negative breast cancer
Article Publication Date